Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer.

IF 0.6 Q4 ONCOLOGY

Case Reports in Oncological Medicine Pub Date : 2022-01-27 eCollection Date: 2022-01-01 DOI:10.1155/2022/2709062

Akira Tsunoda, Toshiro Mizuno, Shohei Iida, Katsunori Uchida, Masako Yamashita, Koshi Sukeno, Hiroki Oka, Yasutaka Tono, Mikiya Ishihara, Kanako Saito, Satoshi Tamaru, Keiichi Yamanaka, Isao Tawara

{"title":"Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer.","authors":"Akira Tsunoda, Toshiro Mizuno, Shohei Iida, Katsunori Uchida, Masako Yamashita, Koshi Sukeno, Hiroki Oka, Yasutaka Tono, Mikiya Ishihara, Kanako Saito, Satoshi Tamaru, Keiichi Yamanaka, Isao Tawara","doi":"10.1155/2022/2709062","DOIUrl":null,"url":null,"abstract":"<p><p>Tumor-related sarcoidosis-like reactions (SLR) have been reported with the use of immune checkpoint inhibitors (ICIs). We report a case of 50-year-old woman who observed an enlarged lymph node in the right hilar region and the appearance of a subcutaneous mass in the extremities during chemotherapy with atezolizumab plus nab-paclitaxel for metastatic triple-negative breast cancer (TNBC). Skin biopsy revealed the formation of epithelioid granulation species with the Langhans giant cell. After discontinuing atezolizumab in the treatment procedure, the hilar lymph nodes and the subcutaneous mass were reduced. A pathological examination was effective in differentiating tumor exacerbation from SLR. Owing to limited information on ICI-related SLR in breast cancer, future studies are recommended to properly manage immune-related adverse effects during cancer treatment.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2022-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813290/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/2709062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Tumor-related sarcoidosis-like reactions (SLR) have been reported with the use of immune checkpoint inhibitors (ICIs). We report a case of 50-year-old woman who observed an enlarged lymph node in the right hilar region and the appearance of a subcutaneous mass in the extremities during chemotherapy with atezolizumab plus nab-paclitaxel for metastatic triple-negative breast cancer (TNBC). Skin biopsy revealed the formation of epithelioid granulation species with the Langhans giant cell. After discontinuing atezolizumab in the treatment procedure, the hilar lymph nodes and the subcutaneous mass were reduced. A pathological examination was effective in differentiating tumor exacerbation from SLR. Owing to limited information on ICI-related SLR in breast cancer, future studies are recommended to properly manage immune-related adverse effects during cancer treatment.

Abstract Image

查看原文本刊更多论文

阿特唑单抗诱导转移性乳腺癌患者结节病样反应

使用免疫检查点抑制剂(ICIs)已报道肿瘤相关结节病样反应(SLR)。我们报告了一例50岁的女性，她在用阿特唑单抗加nab-紫杉醇治疗转移性三阴性乳腺癌(TNBC)期间，观察到右侧门区淋巴结肿大，并在四肢出现皮下肿块。皮肤活检显示朗汉斯巨细胞形成上皮样肉芽。在治疗过程中停用atezolizumab后，肝门淋巴结和皮下肿块减少。病理检查可有效鉴别肿瘤加重与单发复发。由于乳腺癌中ici相关SLR的信息有限，建议未来的研究适当地管理癌症治疗期间免疫相关的不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Case Reports in Oncological Medicine ONCOLOGY-

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Case Reports in Oncological Medicine is a peer-reviewed, Open Access journal that publishes case reports and case series related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer.